Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Aptevo Therapeutics (APVO) Other Non-Current Liabilities (2016 - 2024)

Aptevo Therapeutics (APVO) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $14000.0 as the latest value for Q3 2024.

Quarterly Other Non-Current Liabilities changed N/A to $14000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $14000.0 through Sep 2024, changed N/A year-over-year, with the annual reading at $200000.0 for FY2018, 72.75% down from the prior year.
Other Non-Current Liabilities hit $14000.0 in Q3 2024 for Aptevo Therapeutics, roughly flat from $14000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $14000.0 in Q1 2024 to a low of $14000.0 in Q1 2024.